Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Daniel A Pollyea

Showing results (41-50 of 179) with videos related to

Pageof 18
Sort By:
American Journal of Hematology|April 5, 2019
Optimizing survival outcomes with post-remission therapy in acute myeloid leukemiaBruno C Medeiros, Steven M Chan, Naval G Daver, et al.
Hematological Oncology|September 17, 2011
Impact of TET2 mutations on mRNA expression and clinical outcomes in MDS patients treated with DNA methyltransferase inhibitorsDaniel A Pollyea, Aparna Raval, Brenda Kusler, et al.
Blood Cancer Journal|October 31, 2020
New directions for emerging therapies in acute myeloid leukemia: the next chapterNaval Daver, Andrew H Wei, Daniel A Pollyea, et al.
Bioinformatics (Oxford, England)|November 22, 2015
SomVarIUS: somatic variant identification from unpaired tissue samplesKyle S Smith, Vinod K Yadav, Shanshan Pei, et al.
Open Forum Infectious Diseases|October 13, 2022
Incidence of Invasive Fungal Infections in Patients With Previously Untreated Acute Myeloid Leukemia Receiving Venetoclax and AzacitidineAlexander Zhang, Tanner Johnson, Diana Abbott, et al.
Transplantation and Cellular Therapy|July 28, 2022
Outcomes Are Similar After Allogeneic Hematopoietic Stem Cell Transplant for Newly Diagnosed Acute Myeloid Leukemia Patients who Received Venetoclax + Azacitidine Versus Intensive ChemotherapyAmanda C Winters, Grace Bosma, Diana Abbott, et al.
Blood Advances|July 8, 2020
Glasdegib as maintenance therapy for patients with AML and MDS patients at high risk for postallogeneic stem cell transplant relapseAndrew Kent, Sumithira Vasu, Derek Schatz, et al.
The Journal of Biological Chemistry|January 19, 2011
Reactive oxygen species regulate nucleostemin oligomerization and protein degradationMin Huang, Patrick Whang, Jayanth V Chodaparambil, et al.
American Journal of Hematology|January 6, 2026
Analysis of Patients With Monocytic and Monocytic-Like Acute Myeloid Leukemia, Including AML-M4 and AML-M5, Treated With Venetoclax Plus AzacitidineMarina Konopleva, Courtney D DiNardo, Yan Sun, et al.
Leukemia & Lymphoma|March 13, 2025
Comparison of treatment-related and de novo CCUS: a retrospective analysis from two centersJennifer Santos, Diana Abbott, Grace Bosma, et al.
Pageof 18

Showing results (41-50 of 179) with videos related to

Sort By:
Pageof 18
American Journal of Hematology|April 5, 2019
Optimizing survival outcomes with post-remission therapy in acute myeloid leukemiaBruno C Medeiros, Steven M Chan, Naval G Daver, et al.
Hematological Oncology|September 17, 2011
Impact of TET2 mutations on mRNA expression and clinical outcomes in MDS patients treated with DNA methyltransferase inhibitorsDaniel A Pollyea, Aparna Raval, Brenda Kusler, et al.
Blood Cancer Journal|October 31, 2020
New directions for emerging therapies in acute myeloid leukemia: the next chapterNaval Daver, Andrew H Wei, Daniel A Pollyea, et al.
Bioinformatics (Oxford, England)|November 22, 2015
SomVarIUS: somatic variant identification from unpaired tissue samplesKyle S Smith, Vinod K Yadav, Shanshan Pei, et al.
Open Forum Infectious Diseases|October 13, 2022
Incidence of Invasive Fungal Infections in Patients With Previously Untreated Acute Myeloid Leukemia Receiving Venetoclax and AzacitidineAlexander Zhang, Tanner Johnson, Diana Abbott, et al.
Transplantation and Cellular Therapy|July 28, 2022
Outcomes Are Similar After Allogeneic Hematopoietic Stem Cell Transplant for Newly Diagnosed Acute Myeloid Leukemia Patients who Received Venetoclax + Azacitidine Versus Intensive ChemotherapyAmanda C Winters, Grace Bosma, Diana Abbott, et al.
Blood Advances|July 8, 2020
Glasdegib as maintenance therapy for patients with AML and MDS patients at high risk for postallogeneic stem cell transplant relapseAndrew Kent, Sumithira Vasu, Derek Schatz, et al.
The Journal of Biological Chemistry|January 19, 2011
Reactive oxygen species regulate nucleostemin oligomerization and protein degradationMin Huang, Patrick Whang, Jayanth V Chodaparambil, et al.
American Journal of Hematology|January 6, 2026
Analysis of Patients With Monocytic and Monocytic-Like Acute Myeloid Leukemia, Including AML-M4 and AML-M5, Treated With Venetoclax Plus AzacitidineMarina Konopleva, Courtney D DiNardo, Yan Sun, et al.
Leukemia & Lymphoma|March 13, 2025
Comparison of treatment-related and de novo CCUS: a retrospective analysis from two centersJennifer Santos, Diana Abbott, Grace Bosma, et al.
Pageof 18